我们通过实时检索，整理了近期围绕 INmune Bio Inc.（INMB）人工智能布局的公开报道与信息。以下内容均摘自可核实的来源链接，供读者交叉验证。
Vivo is more than just a platform – it’s your new favorite clinical development colleague, poised to transform clinical trial operation teams’ day-to-day workflow and ability to optimize trial insights with generative AI. Vivo was recently awarded top honors a…
来源：OmniScience Inc. and INmune Bio Inc. Partner to Ac
Vivo is more than just a platform – it’s your new favorite clinical development colleague, poised to transform clinical trial operation teams’ day-to-day workflow and ability to optimize trial insights with generative AI. Vivo was recently · awarded top honors…
来源：OmniScience Inc. and INmune Bio Inc. Partner to Ac
INmune Bio Inc. is a clinical stage biotechnology company that is developing new immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer. Our drug candidates, INKmuneTM and INB03, may be used alone or with con…
来源：INmune Bio | Fierce Biotech
客观分析
INmune Bio Inc.是一家临床阶段生物技术公司，专注于开发免疫疗法以重编程患者先天免疫系统对抗癌症。其与OmniScience合作，引入生成式AI平台Vivo，旨在加速临床试验运营，优化试验洞察。该合作将AI应用于临床开发流程，体现了生物技术领域对数字化工具的接纳，可能提升试验效率与决策质量。